PL1951283T3 - Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika - Google Patents
Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnikaInfo
- Publication number
- PL1951283T3 PL1951283T3 PL06812748T PL06812748T PL1951283T3 PL 1951283 T3 PL1951283 T3 PL 1951283T3 PL 06812748 T PL06812748 T PL 06812748T PL 06812748 T PL06812748 T PL 06812748T PL 1951283 T3 PL1951283 T3 PL 1951283T3
- Authority
- PL
- Poland
- Prior art keywords
- ovarian cancer
- treating
- pharmaceutical composition
- glycoproteins
- polypeptides
- Prior art date
Links
- 206010033128 Ovarian cancer Diseases 0.000 title abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 210000004340 zona pellucida Anatomy 0.000 abstract 3
- 102000003886 Glycoproteins Human genes 0.000 abstract 2
- 108090000288 Glycoproteins Proteins 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 206010027462 Metastases to ovary Diseases 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000011293 immunotherapeutic strategy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73687705P | 2005-11-16 | 2005-11-16 | |
| EP05110819 | 2005-11-16 | ||
| EP06812748A EP1951283B1 (en) | 2005-11-16 | 2006-11-16 | Pharmaceutical composition for treating or preventing ovarian cancer |
| PCT/NL2006/050289 WO2007058536A1 (en) | 2005-11-16 | 2006-11-16 | Pharmaceutical composition for treating or preventing ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1951283T3 true PL1951283T3 (pl) | 2010-12-31 |
Family
ID=37686152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06812748T PL1951283T3 (pl) | 2005-11-16 | 2006-11-16 | Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7968514B2 (pl) |
| EP (1) | EP1951283B1 (pl) |
| CN (1) | CN101365473B (pl) |
| AT (1) | ATE473756T1 (pl) |
| CA (1) | CA2630175C (pl) |
| DE (1) | DE602006015508D1 (pl) |
| PL (1) | PL1951283T3 (pl) |
| WO (1) | WO2007058536A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2809153C (en) * | 2010-08-27 | 2023-09-26 | Pantarhei Bioscience B.V. | Use of hzp3 glycoprotein for treating prostate cancer |
| EP2756100A4 (en) * | 2011-09-15 | 2015-05-13 | Univ Southern California | SPERM PROTEINS AS BIOMARKER FOR OVARY CANCER SCREENING AT EARLY STAGE |
| CN104804075A (zh) * | 2014-01-24 | 2015-07-29 | 中南大学 | 变异的人卵透明带蛋白1和突变基因及检测方法和应用 |
| WO2015154064A2 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| WO2016080830A2 (en) * | 2014-11-18 | 2016-05-26 | Pantarhei Bioscience B.V. | Immunotherapeutic method for treating pancreatic cancer |
| US20210317165A1 (en) | 2018-09-03 | 2021-10-14 | Laboratoire Hra-Pharma | Zp3 fragments in immunotherapy of ovarian cancer |
| EP4419122A1 (en) | 2021-10-19 | 2024-08-28 | Sciencemed Spólka Z Ograniczona Odpowiedzialnoscia | Male contraception |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641487A (en) * | 1989-06-12 | 1997-06-24 | The Government Of The United States Of America As Represented By The Secretary Department Of Health And Human Services | Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides |
| JPH0799974A (ja) * | 1993-10-05 | 1995-04-18 | Tonen Corp | ヒト卵透明帯−２蛋白質をコードするｄｎａ |
| US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| AU763247C (en) * | 1998-02-19 | 2005-05-19 | Eastern Virginia Medical School | Recombinant active human zona pellucida protein 3 (hZP3) |
| US6455041B1 (en) * | 1998-11-17 | 2002-09-24 | Bonita S. Dunbar | Immunogenic epitopes of the human zona pellucida protein (ZP1) |
| AU5909500A (en) * | 1999-07-01 | 2001-01-22 | University Of Georgia Research Foundation, Inc., The | Method and composition for affecting reproductive systems |
| US6455941B1 (en) * | 2001-01-03 | 2002-09-24 | Advanced Semiconductor Engineering, Inc. | Chip scale package |
| CA2539490A1 (en) * | 2003-09-18 | 2005-03-24 | Genmab A/S | Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer |
-
2006
- 2006-11-16 CN CN2006800511848A patent/CN101365473B/zh not_active Expired - Fee Related
- 2006-11-16 WO PCT/NL2006/050289 patent/WO2007058536A1/en active Application Filing
- 2006-11-16 DE DE602006015508T patent/DE602006015508D1/de active Active
- 2006-11-16 US US12/093,908 patent/US7968514B2/en not_active Expired - Fee Related
- 2006-11-16 CA CA2630175A patent/CA2630175C/en active Active
- 2006-11-16 EP EP06812748A patent/EP1951283B1/en active Active
- 2006-11-16 AT AT06812748T patent/ATE473756T1/de not_active IP Right Cessation
- 2006-11-16 PL PL06812748T patent/PL1951283T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE602006015508D1 (de) | 2010-08-26 |
| EP1951283B1 (en) | 2010-07-14 |
| ATE473756T1 (de) | 2010-07-15 |
| WO2007058536A1 (en) | 2007-05-24 |
| CA2630175C (en) | 2018-10-23 |
| US20090060931A1 (en) | 2009-03-05 |
| US7968514B2 (en) | 2011-06-28 |
| EP1951283A1 (en) | 2008-08-06 |
| CN101365473A (zh) | 2009-02-11 |
| CA2630175A1 (en) | 2007-05-24 |
| CN101365473B (zh) | 2013-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014007A (es) | Proteinas de union a epcam y metodos de uso. | |
| MX2009012650A (es) | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. | |
| WO2006081826A3 (en) | Survivin peptide vaccine | |
| PL1951283T3 (pl) | Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika | |
| SA522432139B1 (ar) | بروتينات ربط متعددة الخصوصية لمعالجة السرطان | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| WO2007034489A3 (en) | Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom | |
| MX2023014457A (es) | Peptidos antigenicos para la prevencion y el tratamiento del cancer. | |
| NZ703597A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| MX2011008763A (es) | Peptidos foxm1 y vacunas que contienen los mismos. | |
| SG10201407944TA (en) | Imp-3 oligopeptides and vaccines including the same | |
| MX355054B (es) | Péptido de epítope hig2 y urlc10 y vacunas que contienen el mismo. | |
| EP4406613A3 (en) | Immunogenic arginase peptides | |
| PH12021551372A1 (en) | Human alpha-galactosidase variants | |
| PT1290160E (pt) | Polipeptideos pellino humanos | |
| WO2006023598A3 (en) | Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer | |
| WO2004053092A3 (en) | Human pellino polypeptides | |
| WO2012026820A3 (en) | Immunotherapeutic method for treating prostate cancer | |
| MX2019012083A (es) | Nueva vacuna de peptidos contra la pcsk9. | |
| WO2016080830A3 (en) | Immunotherapeutic method for treating pancreatic cancer | |
| WO2024151583A3 (en) | Vaccines and related methods | |
| ATE315406T1 (de) | Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen |